U.S. Markets open in 5 hrs.

Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
86.26-0.44 (-0.51%)
As of 10:14AM CEST. Market open.
People also watch
Full screen
Previous Close86.70
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range86.16 - 86.81
52 Week Range66.72 - 92.97
Avg. Volume2,431,396
Market Cap105.46B
PE Ratio (TTM)11.93
Earnings DateN/A
Dividend & Yield3.30 (3.35%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
  • Barrons.com2 days ago

    Regeneron: The More the Merrier?

    Last week we noted that when a stock has a big rally, analysts are forced to either cut their rating or raise their target price. Today, Leerink's Geoffrey Porges and Bradley Canino raise their Regeneron target to $573 from $483: After lots of news in the last week, and a major shift in value, and expectations, we are updating our Regeneron model to incorporate higher expected sales of Dupixent (including adult atopic dermatitis, pediatric atopic dermatitis, high eosinophil and non-eosinophilic asthma), lower expected sales of Eylea (accounting for some erosion by RTH258 starting in 2019), and including for the first time revenue from REGN2810, which is the company’s joint (with Sanofi (SNY)) PD-1 antibody.

  • Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
    Zacks2 days ago

    Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

    Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

  • The Wall Street Journal2 days ago

    [$$] Third Point Move Could Lead to Nestlé-L’Oréal Decoupling

    Is Nestlé’s stake in L’Oréal in play? Daniel Loeb is pushing the Swiss food giant to sell its $27.4 billion stake in the French cosmetics firm.